The Latest Breaking News from PFE

Pfizer has underperformed the S&P 500 over the past year, but analysts are moderately optimistic about the stock’s prospects.

The three Polish members of Europe of Sovereign Nations are unhappy with the group’s stance on Russia. But they will not leave it (for now).

Pfizer has underperformed the pharmaceuticals industry over the past year, but analysts are moderately optimistic about the stock’s prospects.

The pharmaceutical industry is evolving continuously with the advancements in drug discovery with Artificial Intelligence (AI), propelling the industry’s growth. Amid this backdrop, quality medical stocks Pfizer (PFE), AstraZeneca (AZN), and Novartis (NVS), which are transforming medicine with AI-powered drug discovery, could be ideal portfolio additions. Continue reading.

Gene therapy stocks are transforming healthcare with revolutionary treatments. Therefore, as this sector continues to evolve, investing in gene therapy stocks like Pfizer (PFE), Sanofi (SNY), and Novartis AG (NVS) could be beneficial. Read on….

March S&P 500 E-Mini futures (ESH25) are down -0.01%, and March Nasdaq 100 E-Mini futures (NQH25) are up +0.08% this morning as investors awaited the latest reading on U.S. job openings, comments from Federal Reserve officials, and corporate earnings reports from heavyweight names.

March S&P 500 E-Mini futures (ESH25) are down -0.21%, and March Nasdaq 100 E-Mini futures (NQH25) are down -0.11% this morning as investors adopted a cautious stance after China retaliated to new U.S. tariffs.

Despite Pfizer trailing behind the broader market over the past year, Wall Street analysts remain moderately bullish about the stock's potential.

For savvy investors, Pfizer could be an undervalued stock to buy here.